Journal article · 2025 · Open access

Comparative Cancer Incidence by Organ Site in Rheumatoid Arthritis Treated with Janus Kinase Inhibitors versus Tumor Necrosis Factor Inhibitors: A Retrospective Real-World Cohort Analysis

Chuanhui Xu, Shiow‐Ing Wang, Ying Ying Leung, James Wei

Biologics, Volume 19, 525–538 · Published 1 August 2025 · DOI 10.2147/btt.s532668

Open PDFView at the publisherCite this paper

In brief

“Comparative Cancer Incidence by Organ Site in Rheumatoid Arthritis Treated with Janus Kinase Inhibitors versus Tumor Necrosis Factor Inhibitors: A Retrospective Real-World Cohort Analysis” is a 2025 journal article by Chuanhui Xu and 3 co-authors, published in Biologics. OpenAlex counts 1 citations as of 19 November 2026, which puts it in the top 9% of works published in 2025 by citations. It is open access under a CC BY-NC licence: the full text is free to read at Biologics.

Citations
1
Most cited in
2026 (1)
Field-weighted impact
0.52
References
36
Authors
4

Abstract

Objective: We aim to evaluate the malignancy risk between Janus kinase inhibitors (JAKi) users and tumor necrosis factor inhibitors (TNFi) users in rheumatoid arthritis (RA) patients, using a large real-world electronic health record database (TriNetX). Methods: In this retrospective cohort study, we identified adult RA patients initiating JAKi or TNFi therapy between January 1, 2018, and December 31, 2022, within the TriNetX global federated network. The hazard ratio (HR) and confidence intervals (CI) of incident-specific cancers, overall cancer incidence, and all-cause mortality, were calculated between the propensity score matched JAKi and TNFi cohorts. The probability of the outcome of interest was estimated using the Kaplan-Meier analysis. Results: After propensity score matching, there were 4045 each in JAKi or TNFi user cohorts. The mean (standard deviation) age was 57.7 (13.3) and 57.6 (13.9) years, 81.4% and 80.8% were female, and median (interquartile range) follow-up time 3.69 (2.61) years vs 3.69 (2.68) years, in the JAKi and the TNFi cohorts, respectively. No significant differences were observed in risks of overall cancer incidence and all-cause mortality between the two cohorts. JAKi users had a reduced risk of incident digestive organ cancers compared with TNFi users (adjusted HR: 0.599, 95% CI: 0.439-0.817), mainly observed among females. The risks of incident respiratory and intrathoracic organs cancers were increased in JAKi users compared to TNFi users among females (adjusted HR: 2.582, 95% CI: 1.109-6.011) but not in males. Conclusion: In a large real-world database, we did not find an increased risk of overall cancer incidence in JAKi compared to TNFi users among RA patients. JAKi users had a lower risk of incident digestive organs cancers, and a higher risk of respiratory cancer in females, when compared with TNFi users.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Xu, C., Wang, S., Leung, Y. Y., & Wei, J. (2025). Comparative Cancer Incidence by Organ Site in Rheumatoid Arthritis Treated with Janus Kinase Inhibitors versus Tumor Necrosis Factor Inhibitors: A Retrospective Real-World Cohort Analysis. Biologics, Volume 19, 525–538. https://doi.org/10.2147/btt.s532668

MLA 9

Xu, Chuanhui, et al. “Comparative Cancer Incidence by Organ Site in Rheumatoid Arthritis Treated with Janus Kinase Inhibitors versus Tumor Necrosis Factor Inhibitors: A Retrospective Real-World Cohort Analysis.” Biologics, vol. Volume 19, 2025, pp. 525–538. https://doi.org/10.2147/btt.s532668.

Chicago

Xu, Chuanhui, Shiow‐Ing Wang, Ying Ying Leung, and James Wei. 2025. “Comparative Cancer Incidence by Organ Site in Rheumatoid Arthritis Treated with Janus Kinase Inhibitors versus Tumor Necrosis Factor Inhibitors: A Retrospective Real-World Cohort Analysis.” Biologics Volume 19: 525–538. https://doi.org/10.2147/btt.s532668.

Harvard

Xu, C. et al. (2025) ‘Comparative Cancer Incidence by Organ Site in Rheumatoid Arthritis Treated with Janus Kinase Inhibitors versus Tumor Necrosis Factor Inhibitors: A Retrospective Real-World Cohort Analysis’, Biologics, Volume 19, pp. 525–538. doi:10.2147/btt.s532668.

IEEE

C. Xu, S. Wang, Y. Y. Leung, and J. Wei, “Comparative Cancer Incidence by Organ Site in Rheumatoid Arthritis Treated with Janus Kinase Inhibitors versus Tumor Necrosis Factor Inhibitors: A Retrospective Real-World Cohort Analysis,” Biologics, vol. Volume 19, pp. 525–538, 2025, doi: 10.2147/btt.s532668.

BibTeX

@article{xu2025comparative,
  title     = {{Comparative Cancer Incidence by Organ Site in Rheumatoid Arthritis Treated with Janus Kinase Inhibitors versus Tumor Necrosis Factor Inhibitors: A Retrospective Real-World Cohort Analysis}},
  author    = {Xu, Chuanhui and Wang, Shiow‐Ing and Leung, Ying Ying and Wei, James},
  journal   = {Biologics},
  year      = {2025},
  volume    = {Volume 19},
  pages     = {525--538},
  doi       = {10.2147/btt.s532668},
  url       = {https://doi.org/10.2147/btt.s532668}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies

  • rheumatoid arthritis
  • JAK inhibitors
  • tumor necrosis factor inhibitors
  • cancer incidence
  • cancer risk
  • digestive organ cancer
  • respiratory cancer
  • sex differences

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Xu, C., Wang, S., Leung, Y. Y., & Wei, J. (2025). Comparative Cancer Incidence by Organ Site in Rheumatoid Arthritis Treated with Janus Kinase Inhibitors versus Tumor Necrosis Factor Inhibitors: A Retrospective Real-World Cohort Analysis. Biologics, Volume 19, 525–538. https://doi.org/10.2147/btt.s532668

How many times has this paper been cited?

1 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Biologics: sign in and open the PDF from this page.

Who wrote this paper?

Chuanhui Xu, Shiow‐Ing Wang, Ying Ying Leung, James Wei.

What is the DOI of this paper?

10.2147/btt.s532668, permanently at https://doi.org/10.2147/btt.s532668. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.